Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.

ABSTRACT:

Importance

Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.

Objective

To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes.

Design, setting, and participants

Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019.

Interventions

Addition of once

SUBMITTER: Petrie MC 

PROVIDER: S-EPMC7157181 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature